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Background: High-density lipoprotein-cholesterol (HDL-C) is a negative risk factor for cardiovascular
events. Although several homogeneous HDL-C assays are available, their accuracy has not been validated,
particularly in subjects with disease. We aimed to clarify whether HDL-C concentrations measured by
homogeneous assays [HDL-C (H)] agree with those determined by the reference measurement pro-
cedures [HDL-C (RMP)] using ultracentrifugation and precipitation with heparin-manganese reagent in
fresh clinical samples.
Methods: HDL-C concentrations in samples from 48 healthy subjects and 119 subjects with disease were
determined using 12 homogeneous assays and RMPs.
Results: All reagents showed excellent intra- and inter-assay CVs (<2.23%) for two pooled sera.
Furthermore, the mean bias was within 1.0% in nine reagents using samples from healthy subjects and
in eight reagents using samples from subjects with disease. In a single HDL-C (H) determination, the total
error requirement of the National Cholesterol Education Program (95% of results < 13%) was fulﬁlled in
nine reagents using samples from healthy subjects and six reagents in those from subjects with disease.
Error component analysis revealed that only one reagent exceeded 10% total error in samples from
healthy subjects, whereas four reagents exceeded this error in samples from subjects with disease.
Correlations between HDL-C (H) and HDL-C (RMP) revealed that the slopes were within 1.00  0.06 in six
reagents in healthy subjects, and eight reagents in subjects with disease.: þ81 3 5684 1609.
r Ltd. Open access under CC BY-NC-ND license.
T. Miida et al. / Atherosclerosis 233 (2014) 253e259254Conclusions: Except for three reagents, HDL-C (H) agrees well with HDL-C (RMP) in subjects with
common disease, but not in those with extremely low HDL-C or abnormal HDL composition.
 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Lipoprotein proﬁles are closely associated with atherosclerotic
disorders such as coronary artery disease and cerebrovascular
disease, the major causes of death in industrialized countries [1,2].
Functionally, serum lipoproteins are divided into two groups:
atherogenic and anti-atherogenic lipoproteins. Atherogenic lipo-
proteins consist of intermediate-density lipoprotein (IDL), low-
density lipoprotein (LDL), and remnant lipoproteins. Over a pro-
longed period of time, these lipoproteins accumulate in macro-
phages in the vascular walls; macrophages turn into foam cells, the
main component of lipid-rich plaques. These are called “vulnerable
plaques” because pro-inﬂammatory cellsdincluding macro-
phagesddegrade the ﬁbrous cap of plaques using proteolytic en-
zymes, causing sudden rupture [3].
High-density lipoprotein (HDL) is the only circulating anti-
atherogenic lipoprotein. HDL removes free cholesterol from so-
matic cells by accepting cell cholesterol via an exchange with the
help of ATP-binding cassette transporter A1 (ABCA1) [4] and G1
(ABCG1) [5]. This reverse cholesterol transport pathway regresses
vascular atheromatous plaques [6]. In clinical practice, the amount
of HDL is expressed as the cholesterol concentration (HDL-C).
Numerous cross-sectional and longitudinal epidemiological studies
have shown that HDL-C is a strong negative risk factor for cardio-
vascular events [7,8]. In both primary and secondary prevention
studies using statins, each 0.0259 mmol/L (1 mg/dL) increase in
HDL-C level decreased the risk of coronary artery disease by 2e3%
[9,10]. Since precipitation methods for HDL-C measurement are
cumbersome and time consuming, HDL-C is measured by homog-
enous assays (so-called “direct assays”) using a variety of principles
in almost all clinical laboratories [11]. In general, homogeneous
assays eliminate or inhibit non-HDL-C with the ﬁrst reagents, and
then solubilize HDL particles for measuring cholesterol with the
second reagents. Although the performance of seven HDL-C ho-
mogeneous assays was investigated recently, the study subjects
included a considerable number of patients with rare dyslipidemia
and extremely low HDL-C [12]. Furthermore, there are additional
novel assays based on different principles.
We examined the precision and accuracy of the HDL-C homo-
geneous assays that are commercially available at present. Using
fresh blood samples from healthy subjects and subjects with dis-
ease, we compared the HDL-C concentrations determined using 12
homogeneous assays [HDL-C (H)] with those determined by the
reference measurement procedures [HDL-C (RMP)].
2. Methods
2.1. Study subjects
This study was planned and carried out concurrently with the
multi-center study of the precision and accuracy of homogeneous
assays for LDL-cholesterol (LDL-C) published previously [13].
Initially, 173 subjects consisting of volunteers and patients with
disease were recruited at the participating institutions. We
excluded dyslipidemic patients with extremely low or high lipo-
protein concentrations [triglyceride (TG)> 11.29mmol/L (1000mg/
dL), LDL-C < 0.52 mmol/L (20 mg/dL), HLD-C < 0.52 mmol/L
(20 mg/dL), and HDL-C > 2.59 mmol/L (100 mg/dL). In addition, we
excluded patients with severe systemic infections, decompensatedliver cirrhosis or cholestatic liver disease [13]. Healthy subjects
(n ¼ 48) were deﬁned as normolipidemic healthy volunteers who
had no abnormal laboratory tests or documented diseases. The
remaining 119 persons were classiﬁed as subjects with disease,
according to their medical history and lipoprotein proﬁles. At
recruitment, written informed consent was obtained from all
subjects.
The study protocol was reviewed and approved by the ethics
committees of all participating institutions. This study was con-
ducted according to the latest version of the Declaration of Helsinki.2.2. Blood sampling and delivery
Fresh venous blood was drawn into vacuum tubes (Venoject II,
VP-AS109K50, Terumo, Tokyo, Japan) from each subject regardless
of time lapsed since the last meal. After the blood was allowed to
clot, the serum was separated within an hour and poured into 50-
mL plastic tubes (430290, Corning Japan, Tokyo) to equalize the
blood components. Aliquots of samples were dispensed into screw-
capped tubes and delivered to either SRL (Hachioji, Japan) for ho-
mogenous assays or Osaka Medical Center for Health Science and
Promotion (OMC-HSP) (Osaka, Japan) for RMP [12]. Samples were
placed in a cooling box containing refrigerant, and carried in a van
equipped with a refrigerator. Temperatures were monitored
continuously at two sites inside the box; temperatures were
maintained between 2 and 4 C within 24 h (Supplemental Fig. 1S).2.3. HDL-C measurement
Within 24 h after blood collection, we measured HDL-C con-
centrations using 12 homogeneous assays, as well as RMPdde-
scribed below. At SRL, the precision and accuracy of 12
homogeneous assays were evaluated (Reagent-A, Denka Seiken;
Reagent-B, Wako; Reagent-C, Sysmex; Reagent-D, Serotec;
Reagent-E, Fureiya; Reagent-F, Kyowa Medex; Reagent-G, Toyobo;
Reagent-H, Shino-Test; Reagent-I, Sekisui Medical; Reagent-J, Ortho
Clinical Diagnostics; Reagent-K, Siemens Healthcare, and Reagent-
L, Beckman Coulter). Reagents-AG, and Reagent-I were original
homogenous assays, whereas Regent-H, Reagent-J, Reagent-K and
Reagent-L were introduced products from other manufacturers
(Supplemental Table S1). Reagents-A to -I were run on the same
automated analyzer (Hitachi-917, also called Hitachi-7170 in Japan)
that was used in the preceding studies [12,13]. The other three
reagents were run on three different instruments manufactured by
the distributors that produced the individual reagents. All of the
reagents, calibrators and controls were supplied by the respective
manufacturers and distributors. Under conditions of anonymity,
the operators of SRL measured HDL-C (H) in triplicate as described
previously [13]. In a preliminary study, we conﬁrmed no cross
contamination between cells, and no condensation during mea-
surements using the Hitachi-910 instrument.
HDL-C was measured by RMP at OMC-HSP. First, two tubes
prepared from each sample were ultracentrifuged at 18 C,
105,000 g for 18.5 h. The bottom fraction was recovered by dis-
carding the ﬂoating fraction using a tube slicer. After adding
heparin-manganese solution to the bottom fraction, we removed
the precipitate by centrifugation (1500 g for 30 min), and ob-
tained the HDL fraction [14]. Finally, wemeasured cholesterol levels
T. Miida et al. / Atherosclerosis 233 (2014) 253e259 255of the supernatant in duplicate as HDL-C (RMP) by the Abelle
Kendall method [15].2.4. Statistical analysis
We determined three CVs (%): CVb, derived from among-run
variation using pooled serum; CVe, derived from within-run vari-
ation using triplicate measurements; and CVd, derived from
patient-speciﬁc errors, as described previously. CVt was calculated
from these three CVs [12,13]. Bias was calculated by subtracting
HDL-C (RMP) from HDL-C (H). Percentage total error (%TE) was
calculated as the sum of %bias and CVt multiplied by 1.96. We used
the criteria of the National Cholesterol Educational Program (NCEP)
for TE requirement for HDL-C measurement, where %bias, CV and %
TE were less than 5, 4 and 13%, respectively [16].3. Results
3.1. Subjects’ characteristics
A total of 173 fresh samples were collected during the study
period. Six subjects were diagnosed with hyper-a-lipoproteinemia
with HDL-C > 2.59 mmol/L, and excluded from the analysis. Of six
patients, two were diagnosed as heterozygotes for cholesteryl ester
transfer protein (CETP) deﬁciency. Neither CETP activities nor
CETP gene mutations were determined in the other patients. In all
subjects, HDL-C ranged from 0.74 to 2.54 mmol/L, and TG ranged
from 0.35 to 10.57 mmol/L (Table S2).3.2. Homogeneous assay precision
In most reagents, the inter- and intra-assay CV values were less
than 1.0% for pooled sera with HDL-C concentrations of 1.29 and
2.13 mmol/L (Table S3). The total CV values were 0.84e2.23%; this
maximum value was about half of the target (4%) proposed by
NCEP.Fig. 1. Box-and-whisker plots of the percentage difference between HDL-C (H) and HDL-C
serum samples were measured using 12 homogeneous assays and RMPs. Percentage differ3.3. Relationship between HDL-C (H) and HDL-C (RMP)
In the healthy group, the %bias values of most samples were
within 13% for all reagents, except Reagent-D. In contrast, a sig-
niﬁcant number of samples in subjects with disease exceeded 20%
for Reagents-G and -L (Fig. 1). The medians deviatedmarkedly from
zero for Reagents-D and -G.
Scatter plots, % bias plots and BlandeAltman plots clearly
showed that Reagents-G and -L had poorer analytical performance
than the other reagents, particularly in the samples from subjects
with disease. In most reagents, HDL-C (H) exhibited good correla-
tion with HDL-C (RMP) in samples from healthy and diseased
subjects (Fig. 2, upper panels). However, the intercepts and slopes
of the linear regression lines ranged from 0.059 to 0.210 mmol/L
and from 0.90 to 1.12 in the samples from healthy subjects, and
from0.016 to 0.316 mmol/L and from 0.89 to 1.01 in samples from
subjects with disease (Table 1). In BlandeAltman plots, the absolute
bias positively correlated with the mean value of HDL-C (H) and
HDL-C (RMP) concentrations for Reagent-D (Fig. 3). There was
marked diversity in the absolute bias independent of the mean
HDL-C values for Reagents-G and -L.
3.4. Total error for single measurements
In samples from healthy subjects, ﬁve reagents fulﬁlled the
requirement of NCEP in all samples, while Reagent-D failed in
almost 40% of samples (Table 2-A). In samples from subjects with
disease, nine reagents reached 90% agreement between HDL-C (H)
and HDL-C (RMP). These reagents showed good agreement in even
samples from patients with severe hypertriglyceridemia or type III
hyperlipidemia (Table S4). In contrast, the percentages of agree-
ment in Reagents-D, -G, and -L were markedly lower.
3.5. Error component analysis
This analysis was less informative than those using scatter plots
and BlandeAltman plots. In samples from healthy subjects, all re-
agents met the NCEP requirement (Table 2-B). In samples from(RMP) in samples from healthy and diseased subjects. HDL-C concentrations in fresh
ences were determined using the ﬁrst measurements of individual reagents.
Fig. 2. Relationship between HDL-C (H) and HDL-C (RMP) in samples from healthy and diseased subjects. Data from healthy and diseased subjects were plotted as scatter graphs
(upper panels) and %bias graphs (lower panels).
T. Miida et al. / Atherosclerosis 233 (2014) 253e259256subjects with disease, Reagents-G and -L did not meet the NCEP
requirement. The CVd value was the critical determinant of these
unfavorable results.
4. Discussion
Our data indicates that the HDL-C (H) concentrations deter-
mined by most of the homogeneous assay reagents agree well with
HDL-C (RMP) determined by CDC reference method procedures in
samples from both healthy and diseased subjects. Nine of the
twelve reagents achieved better than 90% agreementwith the NCEP
total error requirement for a single HDL-C determination (Table 1).In contrast, the HDL-C (H) measured using Reagents-G and -L did
not match the HDL-C (RMP) data over a wide range of HDL-C
concentrations (Fig. 2).
Standardization of homogenous HDL-C assays is problematic
because no pure and stable HDL particles are available for use as a
reference. Apolipoprotein A-I is a better predictor for atheroscle-
rotic disorders than HDL-C, and is already standardized with the
reference material [17]. However, apolipoprotein A-I is not
measured as widely as HDL-C, partly due to the relatively high cost.
In 1994, the Cholesterol Reference Method Laboratory Network
(CRMLN) launched a HDL-C certiﬁcation program for manufac-
turers [18] using the designated comparison method (DCM) and
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(CDCRM). Precipitation methods, such as DCM, cannot completely
precipitate apolipoprotein-B-containing lipoproteins in hyper-
triglyceridemic samples [19]; therefore, wemeasured HDL-C (RMP)
at OMC-HSP by CDCRM, which included removal of chylomicron
and very-low density lipoprotein (VLDL) by slicing a tube after ul-
tracentrifugation, and precipitation of LDL from the bottom fraction
with heparin-manganese solution. Unlike some reagents for LDL-C
homogeneous assays, high TG concentrations were not associated
with discrepancies between HDL-C (H) and HDL-C (RMP) (Table S4,
S5). In addition, the prevalence of postprandial samples did not
increase in the discordant results from diseased subjects (Table S5).
These results suggest that it is acceptable to use postprandial HDL-C
(H) data for calculation of the non-HDL-C concentration.
Miller et al. conducted a similar study of homogenous assays for
HDL-C where they also examined the accuracy of homogeneous
assays for LDL-C [12]. In subjects with disease, our results of error
component analysis were better than those of Miller’s study,
although data were comparable in healthy subjects. We excluded
patients who might have abnormal HDL particles due to genetic
dyslipidemia, severe systemic infection, and decompensated liver
cirrhosis. Furthermore, we also excluded samples with severe
hypertriglyceridemia (TG > 11.29 mmol/L) since chylomicrons ﬂoat
spontaneously on the top of samples, which may cause mechanical
problems with the sampling probes. Error component analysis is
not applicable to samples in which the mean successive difference
between HDL-C (H) and HDL-C (RMP) is large or discontinuous [13].
Miller et al. evaluated samples from 138 subjects with disease,
including those with lecithin-cholesterol acyltransferase (LCAT)
deﬁciency (n ¼ 1), NiemannePick disease type B (n ¼ 1), and pri-
mary biliary cirrhosis (n ¼ 6) [12]. In LCAT deﬁciency, apoA-I con-
taining HDL decreased markedly, while apoE-containing HDL was
comparatively preserved [20]. In Niemann-Pick type B, the sphin-
gomyelin content of HDL particles was greater than that in healthy
subjects [21]. In cholestatic liver diseases such as primary biliary
cirrhosis, apoE-rich HDL increases markedly [22,23]. In the present
study, we excluded samples from subjects with hyper-a-choles-
terolemia (HDL-C > 100 mg/dL) and the abovementioned diseases.
We reported previously that the mean apoE-rich HDL-cholesterol
concentration was more than fourfold greater in hyper-a-choles-
terolemia than in healthy controls [24]. Due to the difference in the
measuring principles, reactivity to apoE-rich HDL may vary mark-
edly among the HDL-C homogeneous assay reagents. Sugiuchi et al.
measured HDL-C in PBC and cholesteryl ester transfer protein
(CETP) deﬁciency using six homogeneous assays. HDL-C (H) ranged
from 51 to 147 mg/dL in PBC, and from 157 to 192 mg/dL in CETP
deﬁciency [23]. Miller’s study is likely to have overemphasized the
inaccuracy of homogenous assays since they included a relatively
high percentage of samples with extremely low HDL-C or
extremely abnormal HDL composition. However, it should be noted
that our data certify the analytical performance of homogenous
assays in samples only from subjects with common diseases.
No signiﬁcant problems were identiﬁed in the error component
analysis ofmost of theHDL-C homogeneous assay reagents (Table 2-
B). Thus, HDL-C homogeneous assays showed generally acceptable
accuracy in the healthy and diseased groups, except for those from a
few commercial sources. However, we suggest the need for further
improvement with respect to standardization when examining the
data in a serial manner. The scatter plots showing the relationships
betweenHDL-C (H) andHDL-C (RMP) revealed that the slopes andY-
intercepts of the regression lines did not fall within the satisfactory
range (1.00  0.03 for slope, and 0.00  0.06 for intercept; Fig. 2,
Table 1). The slopes ranged from 0.90 to 1.12 in the healthy group,
and from 0.89 to 1.09 in the diseased group. Even after excluding
Reagents-D, -G and -L, three other reagents had signiﬁcantly
Fig. 3. BlandeAltman plots of HDL-C (H) and HDL-C (RMP) in samples from healthy and diseased subjects. The X-axis represents the mean HDL-C{¼[HDL-C (H) þ HDL-C (RMP)]/2}.
T. Miida et al. / Atherosclerosis 233 (2014) 253e259258deviated slopes and Y-intercepts in samples from the healthy group,
and four reagents deviated in the diseased group. BlandeAltman
plots indicated the systemic proportional biases in Reagents-B, -D,
-K, and -L in the diseased group (Fig. 3). Because we used HDL-C
values to calculate LDL-C [25] and non-HDL-C, HDL-C values
should be further standardized. We strongly suggest that the man-
ufacturers re-evaluate the HDL-C values of their calibrators using
the same fresh serum.Table 2
Accuracy of HDL-C (H) reagents evaluated with a single measurement (A) and error com
Subjects Reagent
A B C D E
A: Percentage of samples that met the TE requirement of the NCEP for a single HDL-C
Non-diseased subjects (n ¼ 48) 100.0 97.9 97.9 62.5 97
Diseased subjects (n ¼ 119) 93.2 99.1 97.4 75.6 96
B: Error component analysis
Non-diseased subjects (n ¼ 48)
CVb (%)b [1.2] [0.7] [1.2] [1.4] [0.
CVe (%) 0.8 0.5 0.6 0.5 0.6
CVd (%) 3.8 3.3 3.3 4.1 4.2
CVt (%) 4.0 3.4 3.4 4.2 4.3
Mean bias (%) (SD) 0.1 (3.9) 0.9 (3.7) 0.2 (3.5) 2.1 (4.6) 0.5
TE (%), for greater of positive or
negative limit
8.1 7.5 6.9 11.1 9.4
Diseased subjects (n ¼ 119)
CVb (%)b [1.2] [0.7] [1.2] [1.4] [0.
CVe (%) 0.7 0.5 0.7 0.6 0.6
CVd (%) 5.6 3.3 3.4 5.1 4.5
CVt (%) 5.7 3.5 3.6 5.2 4.6
Mean bias (%) (SD) 0.3 (5.9) 0.5 (4.2) 0.2 (3.8) 1.8 (5.3) 0.4
TE (%), for greater of positive or
negative limit
12.4 7.1 7.3 13.0 10
TE, total error.
Based on the method of our previous study [13], we calculated three different CV value
variations due to subject sample-speciﬁc effects, respectively. CVt was calculated as the
a The TE requirement of the NCEP is 95% of results <13%.
b We determined CVb using the pooled serum (Supplemental Table S3, Ref. [13]), andWe conclude that HDL-C (H) concentrations measured using
most of the homogeneous assay reagents (except for Reagents-D,
-G, and -L) agree well with the HDL-C (RMP) concentration as
determined by CDC reference method procedures in healthy and
diseased subjects without extremely low HDL-C or abnormal HDL
particles. The HDL-C homogeneous assays used in the described
criteria enable accurate and rapid determination of HDL-C con-
centrations in the appropriate population.ponent analysis (B).
F G H I J K L
determinationa
.9 100.0 100.0 100.0 100.0 89.6 95.8 91.6
.6 100.0 43.7 92.4 97.5 94.1 97.4 68.1
9] [0.8] [1.2] [1.0] [0.9] [1.1] [1.0] [2.9]
0.4 0.7 0.5 0.6 1.9 0.7 1.7
2.4 4.1 3.0 3.2 3.2 3.2 3.6
2.5 4.2 3.2 3.3 4.3 3.4 4.2
(4.2) 0.8 (2.6) 0.8 (5.0) 1.2 (3.2) 0.3 (3.2) 1.0 (4.0) 0.9 (3.2) 0.4 (3.7)
6.0 9.6 7.8 7.2 9.3 7.4 9.3
9] [0.8] [1.2] [1.0] [0.9] [1.1] [1.0] [2.9]
0.4 0.7 0.6 0.6 1.5 1.0 1.8
2.5 8.0 3.3 3.3 2.8 3.6 7.7
2.6 8.1 3.4 3.5 3.9 3.8 8.0
(4.7) 0.8 (2.8) 3.3 (11.6) 1.6 (3.9) 0.7 (3.9) 0.6 (3.6) 0.2 (4.4) 1.5 (9.5)
.0 6.2 21.4 8.7 7.9 8.1 7.7 19.2
s, CVb, CVe and CVd for (1) inter-assay variations, (2) intra-assay variations, and (3)
square root of CV2b, CV
2
e and CV
2
d.
used the same CVb values in both non-diseased and diseased groups.
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